Silo Pharma partnered with WuXi AppTec to conduct a preclinical small animal study of SPU-16, a central nervous system homing peptide targeting multiple sclerosis. The study will examine the organ/tissue specificity of SPU-16 in an experimental autoimmune encephalomyelitis protocol.